Urology
Volume 74, Issue 4 , Pages 741-745 , October 2009

Efficacy and Safety of Oxybutynin Transdermal System in Spinal Cord Injury Patients With Neurogenic Detrusor Overactivity and Incontinence: An Open-label, Dose-titration Study

  • Michael J. Kennelly

      Affiliations

    • Carolinas Rehabilitation, Charlotte, North Carolina
    • Corresponding Author InformationReprint requests: Michael J. Kennelly, M.D., Carolinas Rehabilitation, Carolinas Healthcare System, 1100 Blythe Boulevard, Charlotte, NC 28203
    • ,
  • Gary E. Lemack

      Affiliations

    • University of Texas Southwestern Medical Center, Dallas, Texas
    • ,
  • Jenelle E. Foote

      Affiliations

    • Midtown Urology and Shepherd Center, Atlanta, Georgia
    • ,
  • Cynthia S. Trop

      Affiliations

    • James J. Peters VA Medical Center, Bronx, New York

Received 9 January 2009 ,Accepted 5 May 2009.

References 

  1. Abrams P, Cardozo L, Fall M, et al. Standardisation Sub-committee of the International Continence Society The standardization of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167–178
  2. Kaplan SA, Chancellor MB, Blaivas JG. Bladder and sphincter behavior in patients with spinal cord lesions. J Urol. 1991;146:113–117
  3. Light JK, Beric A. Detrusor function in suprasacral spinal cord injuries. J Urol. 1992;148:355–358
  4. Weld KJ, Dmochowski RR. Association of level of injury and bladder behavior in patients with post-traumatic spinal cord injury. Urology. 2000;55:490–494
  5. Samson G, Cardenas DD. Neurogenic bladder in spinal cord injury. Phys Med Rehabil Clin N Am. 2007;18:255–274
  6. Tai C, Roppolo JR, de Groat WC. Spinal reflex control of micturition after spinal cord injury. Restor Neurol Neurosci. 2006;24:69–78
  7. Weld KJ, Dmochowski RR. Effect of bladder management on urological complications in spinal cord injured patients. J Urol. 2000;163:768–772
  8. Ethans KD, Nance PW, Bard RJ, et al. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. J Spinal Cord Med. 2004;27:214–218
  9. O'Leary M, Erickson JR, Smith CP, et al. Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury. J Spinal Cord Med. 2003;26:159–162
  10. Madersbacher H, Stöhrer M, Richter R, et al. Trospium chloride versus oxybutynin: a randomized, double-blind, multicenter trial in the treatment of detrusor hyperreflexia. Br J Urol. 1995;75:452–456
  11. Reitz A, Schurch B. Intravesical therapy options for neurogenic detrusor overactivity. Spinal Cord. 2004;42:267–272
  12. Davila GW, Daugherty CA, Sanders SW Transdermal Oxybutynin Study Group. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol. 2001;166:140–145
  13. Weese DL, Roskamp DA, Leach GE, et al. Intravesical oxybutynin chloride: experience with 42 patients. Urology. 1993;41:527–530
  14. Wan J, Rickman C. The durability of intravesical oxybutynin solutions over time. J Urol. 2007;178:1768–1770
  15. Oxytrol [prescribing information]. Corona, CA: Watson Pharma Inc; 2006;
  16. Ditropan [prescribing information]. Kansas City, MO: Sanofi-aventis US LLC; 2008;
  17. Ditropan XL [prescribing information]. Mountain View, CA: ALZA Corporation; 2004;
  18. Appell RA, Chancellor MB, Zobrist RH, et al. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc. 2003;78:696–702
  19. Zobrist RH, Schmid B, Feick A, et al. Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharmacol Res. 2001;18:1029–1034
  20. Dmochowski RR, Davila GW, Zinner NR, et al. Transdermal Oxybutynin Study Group Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol. 2002;168:580–586
  21. Dmochowski RR, Sand PK, Zinner NR, et al. Transdermal Oxybutynin Study Group Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003;62:237–242
  22. Dmochowski RR, Nitti V, Staskin D, et al. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol. 2005;23:263–270
  23. Sand P, Zinner N, Newman D, et al. Oxybutynin transdermal system improves quality of life in adults with overactive bladder: a multicenter, community-based, randomized study. BJU Int. 2007;99:836–844
  24. Marino RJ, Barros T, Biering-Sorensen F, et al. ASIA Neurological Standards Committee 2002 International standards for neurological classification of spinal cord injury. J Spinal Cord Med. 2003;26:S50–S56
  25. Finney SM, Andersson KE, Gillespie JL, et al. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions?. BJU Int. 2006;98:503–507

 This study was supported by Watson Laboratories, Inc, Morristown, New Jersey.

 Editorial assistance was provided by Scientific Connexions, Newtown, Pennsylvania.

 Relevant financial disclosures and conflicts of interest: Michael J. Kennelly. Watson Laboratories, Allergan, Pfizer–Study investigator and consultant and educator/speaker; GSK, Astellas, Novartis—Consultant and educator/speaker; Gary E. Lemack. Allergan–Research support/study site for clinical research; Astellas–Speaker; Novartis–Consultant and speaker; Pfizer–Consultant and speaker; Watson Laboratories–Study investigator (at the time of this study); Jenelle E. Foote. Pfizer–Detrol LA; Astellas/GSK–Vesicare advisory board, speakers bureau; Novartis–Enablex research support, speakers bureau; Allergan–Botox study research support; Pfizer–Fesoterodine research support, speakers bureau; Cynthia S. Trop. Watson Laboratories–Study investigator; Allergan–Botox study investigator.

PII: S0090-4295(09)00629-3

doi: 10.1016/j.urology.2009.05.008

Urology
Volume 74, Issue 4 , Pages 741-745 , October 2009

Article Tools

* Image Usage & Resolution